1Aung T, Chew PT, Yip CC, et al. A randomized doublemasked crossover study comparing latanoprost 0. 005% with unoprestone 0. 12% in patients with primary open - angle glaucoma and ocular hypertension [ J ]. Am J Ophthalmol, 2001,131:636 - 642.
2Ikeda YMori K, Ishibashi T, et al. Latanoprost nonresponders with open- angle glaucoma in the Japanese population[ J]. Jpn J Oph- thalmol, 2006,50:153 - 157.
3Schwartz SG, Puckett BJ, Alien RC, et al. Beta 1 -adrenergic re- ceptor polymorphism and clinical efficacy of betaxolol hydrochloride in normal volunteers [ J ]. Ophthalmology, 2005,112:2131 - 2136.
4Gtlngtir K, Ozkur M, Cascorbi I, et al. Beta 2 - adrenergic receptor polymorphism and susceptibility to primary congenital and open an- gle glaucoma[ J]. Eur J Clin Pharmacol 2003,59:527 - 531.
5McCarty CA, Burmester JK, Mukesh BN, et al. Intraocular pres- sure response to topical 13 - blockers associated with an ADRB2 sin- gle - nucleotide polymorphism [ J ]. Arch Ophthalmol, 2008,126 : 959 - 963.
6Sakurai M, Higashide T, Takahashi M, et al. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost [ J]. Ophthalmlology, 2007, 114: 1039 - 1045.
7刘家琦.实用眼科学(第2版)[M].北京:人民卫生出版社,2002:419.
8Scherer WJ. A retrospective review of non - responders to latano- prost[ J]. J Ocul Pharmacol Ther, 2002,18:287 - 291.
